Verona (VRNA) Talks Up The Long View Following Phase II Setback

By |2019-03-07T14:59:36-05:00January 16th, 2019|Categories: Bill Langbein, Healthcare, Pharmaceutical & Biotechnology, SanaCurrents|Tags: , , , |

Verona Pharma (NASDAQ:VRNA) highlighted a surprising benefit from a lower [...]